Comparative pharmacokinetics of caffeine and three metabolites in clinically normal horses and donkeys

American Journal of Veterinary Research

Volumn 58, Issue 8, 1997, Pages 881-884

  Peck, K ^a   Mealey, K L ^a   Matthews, N S ^a   Taylor, T S ^a  

^a TEXAS A AND M UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAFFEINE; CAFFEINE DERIVATIVE; PARAXANTHINE; THEOBROMINE; THEOPHYLLINE;

ANIMAL EXPERIMENT; ARTICLE; DONKEY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DETERMINATION; DRUG DISPOSITION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HORSE; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN;

ANIMALS; CAFFEINE; EQUIDAE; FEMALE; HORSES; MALE; METABOLIC CLEARANCE RATE; SPECIES SPECIFICITY; THEOBROMINE; THEOPHYLLINE; TIME FACTORS;

ANIMALIA; EQUIDAE; EQUUS ASINUS; EQUUS CABALLUS;

EID: 0030745352     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Golden DL, Spano JS, Wilson RC, et al. Application of an enzyme-multiplied immunoassay technique for determination of caffeine elimination kinetics as a test of liver function in clinically normal dogs. Am J Vet Res 1994;55:790-794.
2. Rall TW. Drugs used in the treatment of asthma. In: Gilman AG, Rail TW, Nies AS, et al, eds. The pharmacological basis of therapeutics. New York: Pergamon Press, 1990;618-637.
3. Aldridge A, Neims AH. The effects of phenobarbital and B-naphthoflavone on the elimination kinetics and metabolite pattern of caffeine in the Beagle dog. Drug Metab Dispos 1979;7:378-382.
4. Tassaneeyakul W, Birkett DJ, McManus ME, et al. Caffeine metabolism by human hepatic cytochromes P450: contributions of 1A2, 2E1, and 3A isoforms. Biochem Pharmacol 1994;47:1767-1766.
5. Gu L, Gonzalez FJ, Kalow W, et al. The biotransformation of caffeine, paraxanthine, theobromine and theophylline by cDNA-expressed human CYP1A2 and CYP2E1. Pharmacogenetics 1992;2:73-77.
6. Boothe DM, Cullen JM, Calvin JA, et al. Antipyrine and caffeine dispositions in clinically normal dogs and dogs with progressive liver disease. Am J Vet Res 1994;55:254-261.
7. Barstow L, Small RE. Liver function assessment by drug metabolism. Pharmacotherapy 1990;10:280-288.
8. Cheng WSC, Murphy TL, Smith MT, et al. Dose dependent pharmacokinetics of caffeine in humans: relevance as a test of quantitative liver function. Clin Pharmacol Ther 1990;47:516-524.
9. Renner E, Weitholtz H, Huguenin P, et al. Caffeine: a model compound for measuring liver function. Hepatology 1984;4:38-46.
10. Schemacher J, Spano JS, Wilson RC, et al. Caffeine clearance in the horse. Vet Res Comm 1994;18:367-372.
11. Aramaki S, Suzuki E, Ishidaka O, et al. Pharmacokinetics of caffeine and its metabolites in horses after intravenous, intramuscular or oral administration. Chem Pharm Bull 1991;39:2999-3002.
12. Mealey KL, Matthews NS, Peck KE, et al. Comparative pharmacokinetics of phenylbutazone and its metabolite oxyphenbutazone in clinically normal horses and donkeys. Am J Vet Res 1996;58:53-55.
13. Miller SM, Matthews NS, Mealey KL, et al. Pharmacokinetics of gentamicin in mammoth asses. J Vet Pharmacol Ther 1994;17:403-406.
14. Horspool JI, McKellar QA. Disposition of oxytetracycline in horses, ponies and donkeys after intravenous administration. Equine Vet J 1990;22:284-285.